Multiple myeloma is a treatable, but currently incurable, hematological malignancy of
plasma cells characterized by diverse and complex tumor genetics for which precision …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most
common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation …

Chemotherapeutic agents have been used for the treatment of numerous cancers, but due to
poor selectivity and severe systemic side effects, their clinical application is limited. Single …

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …

BCMA/CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy
class that shows potent tumor killing activity in multiple myeloma. Here, we investigated a …

Dysregulated apoptosis and proliferation are fundamental properties of cancer, and
microRNAs (miRNA) are critical regulators of these processes. Loss of miR-15a/16-1 at …

Background Cytogenetic abnormalities are common in patients with amyloid light-chain (AL)
amyloidosis; some are associated with poorer outcomes. This post hoc analysis of …

NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and
correlate with poor patient outcomes. Thus, we generated a novel MM model by …

Multiple myeloma is a disorder of the monoclonal plasma cells and is the second most
common hematologic malignancy. Despite improvements in survival with newer treatment …